Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They are a gift. :)
3/20. VDRM VWAP=$.0086 VOLUME=680k Bid nearly all
3/19. VDRM VWAP=$.0089 VOLUME=1k
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
Who is buying these shares, if everything is so, so bad? 575mm shares traded over the past year; about $8.7mm $Volume. NO NEW LOWS AND THERE ARE BUYERS FOR THE SELLERS! I will suggest things aren't as bad as some think! These shares @ $.0085 area are a gift! Bid most of the day for 2.4mm shares...
I do not think the SEC will be wasting their time looking at small time punk company, being ran like a grocery store, like Viad... Trust me, rest assured, the SEC is not onto Doctor O.
I agree: Nothing
I wish that was some kind of consolation
Things are known! Some one somewhere somehow!!!
No reason.
Just asking since someone suggested that someone knew something.
So was wondering because normally when it’s something good that someone might know, the volume would be going through the roof… and because we are about a week away from seeing the Grace Period notice from OTC for non-compliance, was just wondering…
Is the SEC looking into the company???
Did someone file a complaint?
No one selling means also, no one buying. Could be plenty of folks trying to sell, just no buyers
Oh boy... You are a good guy. I love how positive you are. Just do not consume, stay away from drugs.
Beacuse no one selling , ER on Monday or following Monday, will love to hear about new product in Poole line.
Beacuse no one selling , ER on Monday
3/19. VDRM VWAP=$.0089 VOLUME=1k
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
He will need to open a new mental facility then, The VDRM's healed group. He will drive insane the shareholders from the waiting.
Not even chess players are that patient
Busy with Wound Pros.....
Where is the Doc sinking his big head at now? The sad part is that he does not even try to dilute the stock like the rest of the Scumbags CEO the OTCM has, either. It is like he is busy with a new toy and VDRM is just, a thing of yesterday. Now he did dump it into a dark, wet and solitary room..
3/18. VDRM VWAP=$.0082 VOLUME=431k Bid-side nearly all
3/15. VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
It isn’t but it can become one, depending how weak minded the Host is. LMFAO…
Fdc4 isn't that some kind of social disease. LOL
I’ll start nibbling when it hits the 75s
Ouch, wash your filthy mouth kid. What are you doing responding to a bold ass statement from someone with nothing to do? Aren’t you another idiot as well? Welcome to fan club, fanboy…
What a dumb ass statement, just another idiot with nothing to do!
I bet his bold head is shiner than ever now. Nupelo leaves it like that.. Not hair growth but it leaves the heck out of your crane, suave!!! LMAOOOO
Sunshine how is the nupelo working 4 U ?
Needed larger bulding 2 supply my 2 bottlles😄
People, Otiko got kicked out of the old location or is it a facility upgrade?
.🚨 $VDRM
— OTC Updates (@OtcUpdates) March 16, 2024
💰0.0086
Pink Limited, AS: 1.2B, OS: 1.2B, US: 1.1B
Update Delay: 72 hours
Address Updated:
🔴 4640 Admiralty Way, Ste 500, Marina Del Rey, CA, 90292, United States
🟢 5901 W Century Blvd., Ste 750, Los Angeles, CA, 90045,
https://t.co/WXYHM87e1U
Hearing Q2 & Q3 will be done next week and 10k by end of march.
VDRM VWAP=$.0085 VOLUME=337k Bid-side nearly all
3/14. VDRM VWAP=$.0081 VOLUME=1.2mm Bid-side 8x
3/13. VDRM VWAP=$.0087 VOLUME=1.7mm id-side 5x
1-954-251-0616 as per the latest Quarterly filed. You can also find Ms Choes # in the same filing on Page 9.
https://www.otcmarkets.com/otcapi/company/financial-report/391590/content
Which #? Rich’s or STK Financials?
Hahahahahahaha, That was funny: Nigerian Scammer. Good title for a movie tho
If were lucky, someone from the same firm will replace her. IMHO, a new firm will add more cost and more delays get up to speed.
My interest is the forecast issue date, having no past experience with the accounting firm. Rich's email is still richardinza@gmail.com .
Be advised that my message #72051 speaks to my often frustrating experience of his sporadic response to my emails:
(https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173954477).
I don't have that number on me but if you kindly can forward it I will ask and I agree with what you posted
They may be cheap, but there is no volume because this piece of shiat CEO doesn’t update anyone about the company or it’s status since October 2023 and doesn’t file financials on-time on top of that… So what good is it to have cheap shares with no share volume trading???
Since you seem to have the IR persons ears and attention, did you ask about who is actually doing the financials now that Ms Zia Choe has moved on from STK Financial to another company as per the announcement that was PR’d back in January 2024???
If you buy these cheap shares you make a double and you look like a genius if he doesn't file well you didn't lose to much and he may still file and get it done
Wow glad you boy's got that off your chests but this is just like going to a casino game don't bet the farm just play the game take your wins and losses and go home still money to be made
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74600
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |